By 2050, there will be over 1.6 billion adults aged 65 years and older, making age-related diseases and conditions a growing public health concern. One of the leading causes of death in the ageing population is pathogenic infections (e.g. influenza, Streptococcus pneumoniae ). This age-dependent susceptibility to infection has been linked to a reduced ability of the ageing immune system to mount protective responses against infectious pathogens, as well as to vaccines against these pathogens. The primary immune response that promotes protection is the production of antibodies by B cells – a response that is directly mediated by T follicular helper (T FH ) cells within germinal centers (GCs) in secondary lymphoid tissues. In this review, we will summarize the current knowledge on the development and functionality of T FH cells, the use of circulating T FH (cT FH ) cells as vaccine biomarkers, and the influence of age on these processes. Moreover, we will discuss the strategies for overcoming T FH cell dysfunction to improve protective antibody responses in the ageing human population.